Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Molecular Partners AGNASDAQ: MOLN

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets falls 38.1% from a year ago

Total assets stood at CHF 87.4M at the end of Q1 FY2026, down 38.1% from a year earlier and down 14.4% from the prior quarter. Over 3 fiscal years it compounded at -27.0% a year.

Context

  • Total assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps falling in the next quarterly balance sheet after a -38.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 87.4M-14.4% QoQ
Last fiscal yearDec 2025
CHF 102.11M-35.6% YoY
Year agoMar 2025
CHF 141.1M-38.1% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.1%——
1 year-35.6%——
3-year CAGR-27.0%——
5-year CAGR——
10-year CAGR——

Total Assets history

CHF · from the balance sheet

Latest · FY2025
102.11M CHF
Year-over-year change
-35.6%
4-year CAGR
-12.3%

Total Assets vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -38.1% is the 7th highest of 9, against a peer median of -8.1%.
  • Over three fiscal years its annual growth of -27.0% compares with a peer median of -6.1%.
MOLN Competitors
Total Assets for MOLN and competitors
Company Period Latest balance YoY 3-year CAGR
NKTXNkarta, Inc.Mar 2026$372.07M USD-20.9%-5.1%
ALECAlector, Inc.Mar 2026$239.92M USD-41.2%-28.1%
MISTMilestone Pharmaceuticals Inc.Mar 2026$193.73M USD+213.1%+15.1%
PEPGPepGen Inc.Mar 2026$156.3M USD+22.7%-7.2%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$144.48M USD+3.3%+36.4%
MOLNMolecular Partners AGMar 2026CHF 87.4M CHF-38.1%-27.0%
RANIRani Therapeutics Holdings, Inc.Mar 2026$51.88M USD+115.0%-18.4%
CRDFCardiff Oncology, Inc.Mar 2026$49.17M USD-42.0%-18.9%
ELTXElicio Therapeutics, Inc.Mar 2026$22.69M USD-19.4%+4.5%
Peer median (excluding MOLN) —-8.1%-6.1%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents71.81M87.95M67.31M63.87M82.65M
Short-term Investments61M161.2M119.58M85.57M10.41M
Net Receivables25.73M1.7M1.75M286K1.91M
Inventory20000
Other Current Assets0002.31M(1K)
Total Current Assets164.19M254.75M192.46M154.28M96.88M
Property, Plant & Equipment (Net)8.15M7.24M5.68M4.2M5.23M
Goodwill00000
Intangible Assets330K271K212K49K2K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1K(7.51M)000
Total Non-current Assets8.48M7.51M5.89M4.25M5.23M
Total Assets172.67M262.26M198.35M158.53M102.11M
Account Payables4.86M997K410K679K937K
Short-term Debt00000
Tax Payables855K0000
Deferred Revenue28.31M6.41M4.33M00
Other Current Liabilities00001K
Total Current Liabilities46.87M17.25M14.42M10.79M11.03M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)6.93M3.64M000
Other Non-current Liabilities6.74M2.55M5.06M4.88M8.31M
Total Non-current Liabilities18.51M9.84M7.51M6.11M10.75M
Total Liabilities65.38M27.09M21.92M16.89M21.77M
Common Stock3.23M3.6M3.64M4.04M4.04M
Retained Earnings(250.95M)(127.78M)(191.76M)(246.29M)(311.75M)
Accumulated OCI0(981K)000
Other Stockholders Equity0(0)(0)00
Minority Interest00000
Total Equity107.29M235.17M176.43M141.64M80.33M
Total Debt6.04M4.85M3.65M2.44M3.64M
Net Debt(65.77M)(83.1M)(63.66M)(61.43M)(79.01M)

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.